ES2175798T3 - Cd8 como un inhibidor del sistema inmunitario celular. - Google Patents

Cd8 como un inhibidor del sistema inmunitario celular.

Info

Publication number
ES2175798T3
ES2175798T3 ES98950218T ES98950218T ES2175798T3 ES 2175798 T3 ES2175798 T3 ES 2175798T3 ES 98950218 T ES98950218 T ES 98950218T ES 98950218 T ES98950218 T ES 98950218T ES 2175798 T3 ES2175798 T3 ES 2175798T3
Authority
ES
Spain
Prior art keywords
inhibitor
immune system
cellular immune
medicament
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98950218T
Other languages
English (en)
Inventor
Bent Karsten John Rad Jakobsen
George Fu Gao
Ulrich Conrad Gerth
Andrew Kelvin John Radc Sewell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avidex Ltd
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidex Ltd filed Critical Avidex Ltd
Application granted granted Critical
Publication of ES2175798T3 publication Critical patent/ES2175798T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

El uso de una molécula de CD8 o a soluble que comprende un dominio de inmunoglobulina plegado correctamente, en la fabricación de un medicamento para una terapia inmunosupresora.
ES98950218T 1997-10-28 1998-10-28 Cd8 como un inhibidor del sistema inmunitario celular. Expired - Lifetime ES2175798T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9722779.7A GB9722779D0 (en) 1997-10-28 1997-10-28 Human CD8 as an inhibitor of the cellular immune system

Publications (1)

Publication Number Publication Date
ES2175798T3 true ES2175798T3 (es) 2002-11-16

Family

ID=10821228

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98950218T Expired - Lifetime ES2175798T3 (es) 1997-10-28 1998-10-28 Cd8 como un inhibidor del sistema inmunitario celular.

Country Status (17)

Country Link
US (1) US20070191278A1 (es)
EP (1) EP1024822B1 (es)
JP (1) JP2001521005A (es)
KR (1) KR100585246B1 (es)
CN (1) CN1256147C (es)
AT (1) ATE215833T1 (es)
AU (1) AU752910B2 (es)
CA (1) CA2308463A1 (es)
DE (1) DE69804839T2 (es)
DK (1) DK1024822T3 (es)
ES (1) ES2175798T3 (es)
GB (1) GB9722779D0 (es)
HK (1) HK1031099A1 (es)
NO (1) NO20002148L (es)
NZ (1) NZ504240A (es)
PT (1) PT1024822E (es)
WO (1) WO1999021576A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929993D0 (en) * 1999-12-17 2000-02-09 Avidex Ltd Substances
GB0107628D0 (en) * 2001-03-27 2001-05-16 Avidex Ltd Substances
GB0114533D0 (en) * 2001-06-14 2001-08-08 Avidex Ltd Substances
GB0115071D0 (en) * 2001-06-20 2001-08-15 Avidex Ltd Substances
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
GB2398300A (en) * 2003-02-17 2004-08-18 Isis Innovation Method and compositions for boosting immune response
CN101068574B (zh) * 2004-07-20 2012-07-18 伊索格尼斯股份有限公司 与自身抗原有关的自身免疫和疾病的特异性抑制
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
US8871515B2 (en) 2008-09-17 2014-10-28 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
KR102243575B1 (ko) * 2010-12-09 2021-04-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
EP3270951B1 (en) 2015-03-16 2020-09-09 California Institute of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
US20170319722A1 (en) * 2016-04-04 2017-11-09 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
AU5342290A (en) * 1989-03-15 1990-10-09 David R. Kaplan Cd8-based pharmaceuticals
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5645837A (en) * 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same

Also Published As

Publication number Publication date
DE69804839D1 (de) 2002-05-16
JP2001521005A (ja) 2001-11-06
NO20002148D0 (no) 2000-04-27
PT1024822E (pt) 2002-09-30
DE69804839T2 (de) 2002-10-10
GB9722779D0 (en) 1997-12-24
KR100585246B1 (ko) 2006-06-01
HK1031099A1 (en) 2001-06-01
CN1283120A (zh) 2001-02-07
CA2308463A1 (en) 1999-05-06
EP1024822B1 (en) 2002-04-10
WO1999021576A1 (en) 1999-05-06
NO20002148L (no) 2000-06-27
ATE215833T1 (de) 2002-04-15
KR20010024570A (ko) 2001-03-26
NZ504240A (en) 2002-11-26
EP1024822A1 (en) 2000-08-09
AU9637498A (en) 1999-05-17
CN1256147C (zh) 2006-05-17
DK1024822T3 (da) 2002-08-05
AU752910B2 (en) 2002-10-03
US20070191278A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
ES2175798T3 (es) Cd8 como un inhibidor del sistema inmunitario celular.
DK1036059T3 (da) Adamantanderivater
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
AR012673A1 (es) Compuesto de ester de etilenglicol de monohidrobenzoporfirina utiles para terapia fotodinamica, composiciones farmaceuticas y uso de los mismos.
EE200000320A (et) Uudsed ühendid
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
AR025163A1 (es) Un procedimiento para preparar olefinas, un sistema catalizador soportado, el uso de un compuesto catalizador del grupo 15 que contiene hafnio y el uso deun sistema catalizador que comprende un compuesto catalizador
UY26297A1 (es) Vacuna
BR0010418B1 (pt) microorganismo de salmonella, composiÇço de vacina e uso do referido microorganismo.
AR025330A1 (es) Combinacion de sustancias activas con clonidina
MXPA03001945A (es) Tetrahidroindazoles sustituidos con arilo y su uso como ligandos para el receptor gaba-a.
DE59300631D1 (de) Biologisch abbaubare, wässrige Dispersionen.
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
DOP2002000457A (es) Tetrahidroquinolinas
ES2174489T3 (es) Aminoalquiltrialquilsililcelulosa y un procedimiento para el revestimiento de superficies.
SV1997000025A (es) Nuevos pirimido /1,2-a/ indoles ref. lea 31544-sv
SE9604581D0 (sv) An agent against cancer and virus infections
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
AR005704A1 (es) Heteroariloxazolidinonas
ITRM910460A0 (it) Valvola di non ritorno per condutture di gas.
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2165020T3 (es) Monohidrato de famciclovir.
ES1033176Y (es) Sistema de aprovechamiento dea aguas ya utilizadas para su uso en el inodoro.
ECSP941089A (es) Agentes arilantes
AR023389A1 (es) Nuevo uso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1024822

Country of ref document: ES